11/20
09:05 am
ptct
InnovationRx: Trump Picks RFK, Jr. And Dr. Oz For Key Healthcare Roles [Forbes]
Medium
Report
InnovationRx: Trump Picks RFK, Jr. And Dr. Oz For Key Healthcare Roles [Forbes]
11/19
11:09 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $51.00 to $62.00. They now have an "overweight" rating on the stock.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $51.00 to $62.00. They now have an "overweight" rating on the stock.
11/19
03:02 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/15
04:26 pm
ptct
Child Thriving After Becoming World's Youngest to Receive Gene Therapy for AADC Deficiency [Yahoo! Finance]
Neutral
Report
Child Thriving After Becoming World's Youngest to Receive Gene Therapy for AADC Deficiency [Yahoo! Finance]
11/14
02:03 pm
ptct
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain [Yahoo! Finance]
Low
Report
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain [Yahoo! Finance]
11/13
06:07 pm
ptct
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy [Yahoo! Finance]
Medium
Report
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy [Yahoo! Finance]
11/13
06:02 pm
ptct
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
Medium
Report
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
11/11
11:15 pm
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/11
11:15 pm
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/11
11:18 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Barclays PLC from $31.00 to $43.00. They now have an "equal weight" rating on the stock.
Medium
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Barclays PLC from $31.00 to $43.00. They now have an "equal weight" rating on the stock.
11/9
08:10 am
ptct
PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/8
10:19 am
ptct
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
11/7
06:40 pm
ptct
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/7
04:01 pm
ptct
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Low
Report
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
11/6
11:24 am
ptct
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics [Yahoo! Finance]
Low
Report
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics [Yahoo! Finance]
11/6
07:21 am
ptct
PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Low
Report
PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
11/4
04:45 pm
ptct
PTC Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
PTC Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]
11/4
04:30 pm
ptct
PTC Therapeutics to Participate at Upcoming Investor Conferences
Low
Report
PTC Therapeutics to Participate at Upcoming Investor Conferences
10/30
07:00 am
ptct
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
Medium
Report
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
10/25
04:30 pm
ptct
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/24
07:00 am
ptct
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
Low
Report
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
10/18
06:30 am
ptct
CHMP Maintains Negative Opinion on Translarna™ Reexamination
Medium
Report
CHMP Maintains Negative Opinion on Translarna™ Reexamination
10/14
04:30 pm
ptct
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
Medium
Report
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
10/11
12:46 pm
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Morgan Stanley from $32.00 to $45.00. They now have an "equal weight" rating on the stock.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Morgan Stanley from $32.00 to $45.00. They now have an "equal weight" rating on the stock.
10/10
11:01 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at Raymond James. They set a "market perform" rating on the stock.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at Raymond James. They set a "market perform" rating on the stock.